Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BRNS 
Barinthus Biotherapeutics plc (BRNS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: BRNS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.5
1 Year Target Price $4.5
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.01% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 42.75M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 3 | Beta -0.74 | 52 Weeks Range 0.64 - 2.91 | Updated Date 09/17/2025 |
52 Weeks Range 0.64 - 2.91 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -360.87% |
Management Effectiveness
Return on Assets (TTM) -21.35% | Return on Equity (TTM) -53.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -31516860 | Price to Sales(TTM) 2.86 |
Enterprise Value -31516860 | Price to Sales(TTM) 2.86 | ||
Enterprise Value to Revenue 0.62 | Enterprise Value to EBITDA -6.67 | Shares Outstanding 40718200 | Shares Floating 35677312 |
Shares Outstanding 40718200 | Shares Floating 35677312 | ||
Percent Insiders 13.65 | Percent Institutions 44.49 |
Upturn AI SWOT
Barinthus Biotherapeutics plc
Company Overview
History and Background
Barinthus Biotherapeutics plc, formerly known as Vaccitech plc, is a biopharmaceutical company focused on developing novel T cell immunotherapeutic candidates designed to treat and prevent infectious diseases, autoimmune diseases, and cancer. Vaccitech was founded in 2010 based on technology developed at the University of Oxford. They have made strategic shifts in pipeline focus and corporate structure.
Core Business Areas
- Infectious Diseases: Development of immunotherapeutics and vaccines for infectious diseases, including Hepatitis B.
- Autoimmune Diseases: Developing therapies which use the human immune system to modify the effects of auto-immune diseases.
- Oncology: Development of cancer immunotherapies, leveraging their T cell activation platform.
Leadership and Structure
The leadership team consists of seasoned executives with experience in biotechnology and pharmaceutical development. The organizational structure likely involves research and development, clinical operations, and commercial strategy divisions.
Top Products and Market Share
Key Offerings
- VTP-300 (Hepatitis B): VTP-300 is a therapeutic vaccine being developed for chronic hepatitis B infection. Data from trials is pending. Competitors include companies developing curative therapies for Hep B, such as Assembly Biosciences and Vir Biotechnology.
- VTOX Platform: A platform technology designed to induce, expand, and maintain regulatory T cells (Tregs) for autoimmune diseases and potential applications in oncology. No current market share data. Competitors include other companies developing Treg therapies, such as Sangamo Therapeutics.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high R&D costs, and long development timelines. The market for immunotherapies is rapidly growing, driven by advancements in immunology and personalized medicine.
Positioning
Barinthus Biotherapeutics positions itself as a developer of novel T cell immunotherapies, targeting areas with high unmet medical need. Their competitive advantage lies in their proprietary platform technology.
Total Addressable Market (TAM)
The Hepatitis B market is expected to reach billions of dollars. The autoimmune market is even larger. Barinthus Biotherapeutics is positioned to capture a share of these markets through successful clinical development and commercialization of their therapies.
Upturn SWOT Analysis
Strengths
- Proprietary T cell immunotherapy platform
- Experienced management team
- Focus on areas with high unmet medical need
- Partnerships with leading research institutions
Weaknesses
- Limited number of products in late-stage development
- High R&D costs
- Dependence on clinical trial success
- Relatively small market cap, limiting access to capital
Opportunities
- Expansion of pipeline through internal development and acquisitions
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Increased awareness of the potential of immunotherapies
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- VIR
- ABUS
- GILD
Competitive Landscape
Barinthus Biotherapeutics faces intense competition from larger pharmaceutical companies with greater resources. Their success depends on demonstrating the efficacy and safety of their therapies in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been marked by the transition to Barinthus Biotherapeutics, pipeline advancement, and clinical trial progress.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals. Analyst estimates vary.
Recent Initiatives: Recent initiatives include focusing on pipeline assets such as VTP-300 and the VTOX platform.
Summary
Barinthus Biotherapeutics is a biopharmaceutical company developing T cell immunotherapies. Its strengths lie in its platform technology and experienced management team. However, the company faces challenges including clinical trial risk and competition. Successful development and commercialization of its pipeline assets are critical for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Barinthus Biotherapeutics plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-04-30 | CEO, Director & Principal Financial Officer Mr. William J. Enright MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 105 | Website https://www.barinthusbio.com |
Full time employees 105 | Website https://www.barinthusbio.com | ||
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunotherapeutic candidate for prostate cancer; VTP-600, an immunotherapeutic candidate targeting MAGE-A3 and NY-ESO1 antigens; VTP-500, a prophylactic vaccine candidate to prevent middle east respiratory syndrome; VTP-400, a prophylactic vaccine candidate for shingles; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.